Tissue Proteomics pp 177-184 | Cite as
Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness
- 1 Mentions
- 865 Downloads
Abstract
Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.
Keywords
Breast cancer mTRAQ Selected reaction monitoringAbbreviations
- DDA
Data-dependent acquisition
- ER
Estrogen receptor
- G1
Tumor grade 1
- G3
Tumor grade 3
- iTRAQ
Isobaric tags for relative and absolute quantitation
- MIDAS™
MRM initiated detection and sequencing
- mTRAQ
Mass differential tags for relative and absolute quantification
- mTRAQ-SRM
Selected reaction monitoring with mTRAQ labeling
- PR
Progesterone receptor
- SRM
Selected reaction monitoring
- TEAB
Triethylammonium bicarbonate
Notes
Acknowledgments
We would like to thank Rudolf Nenutil for his pathological guidance. We also thank Parhom Towfighi (UCSF Medical Centre) for his work on editing for the book. This work was supported by Czech Science Foundation (Project No. 17-05957S).
No conflict of interests.
References
- 1.Ferlay J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403CrossRefPubMedGoogle Scholar
- 2.Bundred NJ (2001) Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27(3):137–142CrossRefPubMedGoogle Scholar
- 3.Parker CE, Borchers CH (2014) Mass spectrometry based biomarker discovery, verification, and validation – quality assurance and control of protein biomarker assays. Mol Oncol 8(4):840–858CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Tabb DL et al (2010) Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res 9(2):761–776CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Leitner A, Aebersold R (2013) SnapShot: mass spectrometry for protein and proteome analyses. Cell 154(1):252–252.e1CrossRefPubMedGoogle Scholar
- 6.Marx V (2013) Targeted proteomics. Nature Methods 10:19–22CrossRefPubMedGoogle Scholar
- 7.Bouchal P et al (2015) Combined proteomics and transcriptomics identifies carboxypeptidase B1 and nuclear factor kappaB (NF-kappaB) associated proteins as putative biomarkers of metastasis in low grade breast cancer. Mol Cell Proteomics 14(7):1814–1830CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Lowry OH et al (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275PubMedGoogle Scholar
- 9.MacLean B et al (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26(7):966–968CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Holzmann J et al (2009) Stoichiometry determination of the MP1-p14 complex using a novel and cost-efficient method to produce an equimolar mixture of standard peptides. Anal Chem 81(24):10254–10261CrossRefPubMedGoogle Scholar
- 11.Bouchal P et al (2009) Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J Proteome Res 8(1):362–373CrossRefPubMedGoogle Scholar
- 12.Domanski D et al (2012) MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 12(8):1222–1243CrossRefPubMedGoogle Scholar